Have a feature idea you'd love to see implemented?
Let us know!
NNVC Nanoviricides Inc
Price (delayed)
$1.28
Market cap
$18.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.76
Enterprise value
$14.5M
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped
Highlights
NNVC's debt has shrunk by 100% YoY
The EPS has contracted by 9% from the previous quarter but it has grown by 2.6% YoY
NNVC's quick ratio has dropped by 68% year-on-year and by 33% since the previous quarter
The equity has declined by 22% year-on-year and by 12% since the previous quarter
Key stats
What are the main financial stats of NNVC
Market
Valuations
Earnings
Shares outstanding
14.35M
Market cap
$18.36M
Enterprise value
$14.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$9.44M
EBITDA
-$8.67M
Free cash flow
-$7.93M
Per share
Balance sheet
Liquidity
EPS
-$0.76
Free cash flow per share
-$0.58
Book value per share
$0.69
Revenue per share
$0
TBVPS
$0.83
Total assets
$11.74M
Total liabilities
$1.63M
Debt
$0
Equity
$10.11M
Working capital
$2.41M
Debt to equity
0
Current ratio
2.48
Quick ratio
2.37
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-76.5%
Return on equity
-84.6%
Return on invested capital
-144.4%
Return on capital employed
-93.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NNVC stock price
How has the Nanoviricides stock price performed over time
Intraday
-3.76%
1 week
-4.48%
1 month
-12.93%
1 year
17.43%
YTD
25.49%
QTD
-14.67%
Financial performance
How have Nanoviricides's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.65M
Net income
-$9.45M
Gross margin
N/A
Net margin
N/A
NNVC's net income is down by 14% QoQ and by 5% YoY
Nanoviricides's operating income has decreased by 13% QoQ and by 3.2% YoY
Growth
What is Nanoviricides's growth rate over time
Valuation
What is Nanoviricides stock price valuation
P/E
N/A
P/B
1.86
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 9% from the previous quarter but it has grown by 2.6% YoY
The stock's price to book (P/B) is 24% more than its 5-year quarterly average of 1.5 and 24% more than its last 4 quarters average of 1.5
The equity has declined by 22% year-on-year and by 12% since the previous quarter
Efficiency
How efficient is Nanoviricides business performance
Nanoviricides's return on equity has shrunk by 55% YoY and by 21% QoQ
NNVC's return on assets has dropped by 51% year-on-year and by 22% since the previous quarter
Nanoviricides's return on invested capital has decreased by 32% YoY and by 27% QoQ
Dividends
What is NNVC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NNVC.
Financial health
How did Nanoviricides financials performed over time
NNVC's quick ratio has dropped by 68% year-on-year and by 33% since the previous quarter
The current ratio has shrunk by 67% YoY and by 32% QoQ
NNVC's debt is 100% lower than its equity
NNVC's debt has shrunk by 100% YoY
NNVC's debt to equity has dropped by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.